Heron Therapeutics Maintains $6 Price Target Despite Reiterated Buy Rating from HC Wainwright & Co.

Heron Therapeutics (HRTX) received a Buy rating and $6 price target from HC Wainwright & Co. Analyst Brandon Folkes maintained the rating and price target, citing confidence in the company's performance outlook. The stock has a Buy rating from 4 analysts, with an average target price of $4.50 and a high estimate of $6.00. The estimated GF Value for HRTX in one year is $2.07, suggesting a 38.46% upside from the current price.